Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
June 2003

Topical Tacrolimus Is a Useful Adjunctive Therapy for Bullous Pemphigoid

Author Affiliations

Not Available


Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003

Arch Dermatol. 2003;139(6):813-815. doi:10.1001/archderm.139.6.813

Bullous pemphigoid (BP), which is the most common autoimmune bullous disease, is characterized by tense blisters and erosions and often is associated with preceding or concurrent fixed urticaria.1 Although systemic therapy is typically used for BP, a recent randomized controlled trial demonstrated that BP also responds very effectively to treatment with topical corticosteroids.2 Optimizing a topical BP therapy is desirable, since BP often affects the elderly, who are susceptible to the adverse effects of systemic drugs.3 Topical formulations of the macrolide immunosuppressant tacrolimus have proved effective in atopic dermatitis, but the use of topical tacrolimus in other skin diseases has only been partially explored.4,5 Herein, we describe 2 patients with BP who responded well to topical tacrolimus (0.1% Protopic ointment) therapy.